TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31133585

Group type: EXPERIMENTAL
Intervention: BHiRCH intervention (early warning tool, care pathway, structured communication method)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 14
Study: 28801165

Group type: EXPERIMENTAL
Intervention: Immediate Intervention with a child care health consultant (CCHC) in Year 1
Number of subjects: 32

Group type: COMPARATOR
Intervention: Delayed intervention (contrast) group
Number of subjects: 32
Study: 25660356

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 353

Group type: COMPARATOR
Intervention: Rosuvastatin 10 mg
Number of subjects: 353

Group type: COMPARATOR
Intervention: Rosuvastatin 40 mg
Number of subjects: 353
Study: 23422453

Group type: EXPERIMENTAL
Intervention: Vibration therapy (twice a week for 3 months)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Physiotherapy treatment (PT)
Number of subjects: 89
Study: 20525942

Group type: EXPERIMENTAL
Intervention: Atomoxetine (1.2 mg/kg/day)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Atomoxetine (0.5 mg/kg/day)
Number of subjects: 41
Study: 20573584

Group type: EXPERIMENTAL
Intervention: Schizophrenia patients
Number of subjects: 70

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 70
Study: 17257238

Group type: EXPERIMENTAL
Intervention: 100 mg sumatriptan
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 15097434

Group type: EXPERIMENTAL
Intervention: HL-450 (AR milk thickened with 0.45 g/100 mL LBG)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: HL-350 (AR milk with reduced concentration of 0.35 g/100 mL LBG)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control milk (HL-00; no LBG)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: HL-450
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: HL-350
Number of subjects: 30
Study: 12208906

Group type: EXPERIMENTAL
Intervention: Manual traction
Number of subjects: 87

Group type: COMPARATOR
Intervention: Fracture-table traction
Number of subjects: 87
Study: 9639214

Group type: EXPERIMENTAL
Intervention: Forceps delivery
Number of subjects: 44

Group type: COMPARATOR
Intervention: Vacuum delivery
Number of subjects: 44
Study: 8613331

Group type: EXPERIMENTAL
Intervention: 0.1 ml BCG vaccine at birth
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: 0.05 ml BCG vaccine at birth
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: 0.1 ml BCG vaccine at 4-6 weeks
Number of subjects: 238

Group type: COMPARATOR
Intervention: Control group (0.1 ml BCG at birth)
Number of subjects: 238
Study: 2813804

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control
Number of subjects: 9
Study: 1091940

Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg during detoxification
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol 20 mg during detoxification
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol 10 mg given 2 hrs before 30 mg morphine i.v.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control) during detoxification
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control) given 2 hrs before morphine
Number of subjects: 0
Study: 31626050

Group type: EXPERIMENTAL
Intervention: PCV13 (3, 4, 5 months)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PCV13 (2, 4, 6 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: PCV13 (3, 5 months)
Number of subjects: 0
Study: 28716230

Group type: EXPERIMENTAL
Intervention: Interferon β-1a injected subcutaneously three times weekly (IFN β‐1a SC tiw)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interferon β-1a injected intramuscularly once weekly (IFN β‐1a IM qw)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interferon β-1a IM qw
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interferon β-1a SC tiw
Number of subjects: 0
Study: 27845597

Group type: EXPERIMENTAL
Intervention: Numerical information about benefits and harms of cervical screening
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Numerical information specific to HPV-vaccinated women
Number of subjects: 1000

Group type: COMPARATOR
Intervention: No information
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Non-numerical information
Number of subjects: 1000
Study: 25288125

Group type: EXPERIMENTAL
Intervention: 0.018-inch bracket slot system
Number of subjects: 216

Group type: COMPARATOR
Intervention: 0.022-inch bracket slot system
Number of subjects: 216
Study: 23021098

Group type: EXPERIMENTAL
Intervention: Brief Negotiation Interview (BNI)
Number of subjects: 342
Study: 19940322

Group type: EXPERIMENTAL
Intervention: Power Training (PT)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Wait-list Control
Number of subjects: 45
Study: 17710008

Group type: EXPERIMENTAL
Intervention: EMLA (5 g)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (neomycin ointment 5 g)
Number of subjects: 60
Study: 15596745

Group type: EXPERIMENTAL
Intervention: IV immunoglobulins (IVIg) 1 g/kg
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo (0.1% human albumin)
Number of subjects: 76
Study: 11516593

Group type: EXPERIMENTAL
Intervention: Concurrent treatment (smoking cessation intervention initiated two weeks after admission)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Delayed treatment (smoking cessation intervention initiated six weeks after admission)
Number of subjects: 36
Study: 9577422

Group type: EXPERIMENTAL
Intervention: Total hip replacement
Number of subjects: 372
Study: 7833096

Group type: COMPARATOR
Intervention: MACC chemotherapy
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: MACC chemotherapy + Lonidamine (LND) 150 mg orally three times daily
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: MACC chemotherapy + LND
Number of subjects: 151

Group type: COMPARATOR
Intervention: MACC chemotherapy (control)
Number of subjects: 151
Study: 3240760

Group type: EXPERIMENTAL
Intervention: Lignocaine jelly and spray combination
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Lignocaine jelly alone
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Lignocaine spray alone
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (no lignocaine)
Number of subjects: 94
Study: 31958099

Group type: EXPERIMENTAL
Intervention: Lumbar spine orthosis (n=23)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No lumbar spine orthosis (n=27)
Number of subjects: 50
Study: 31230007

Group type: EXPERIMENTAL
Intervention: Methadone plus daily placebo dose-extension (PDE)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Methadone/treatment as usual (control)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 120
Study: 28474311

Group type: EXPERIMENTAL
Intervention: TRUS-guided compression on bleeding biopsy tracts immediately after prostate biopsy
Number of subjects: 148

Group type: COMPARATOR
Intervention: TRUS-guided prostate biopsy alone (non-compression group)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: TRUS-guided compression
Number of subjects: 148
Study: 25875868

Group type: EXPERIMENTAL
Intervention: Study vaccine (trivalent, inactivated split influenza vaccine)
Number of subjects: 405

Group type: COMPARATOR
Intervention: Control vaccine (commercially available trivalent, inactivated split influenza vaccine)
Number of subjects: 405
Study: 23928664

Group type: EXPERIMENTAL
Intervention: Intranasal insulin (40 IU)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 21545398

Group type: EXPERIMENTAL
Intervention: aliskiren/HCTZ 150/12.5 mg, titrated to 300/25 mg
Number of subjects: 332

Group type: COMPARATOR
Intervention: amlodipine 5 mg, titrated to 10 mg
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: aliskiren/HCTZ
Number of subjects: 332

Group type: COMPARATOR
Intervention: amlodipine
Number of subjects: 332
Study: 19549078

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 29

Group type: COMPARATOR
Intervention: Nefazodone
Number of subjects: 29
Study: 17971584

Group type: EXPERIMENTAL
Intervention: COX‐2 methylated tumors
Number of subjects: 177

Group type: COMPARATOR
Intervention: COX‐2 expression (IHC)
Number of subjects: 177
Study: 16215314

Group type: EXPERIMENTAL
Intervention: Urethral injection of 100 units of botulinum A toxin (n=20)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Medical treatment as controls (n=10)
Number of subjects: 30
Study: 11850304

Group type: EXPERIMENTAL
Intervention: β-blockers
Number of subjects: 0
Study: 9988956

Group type: EXPERIMENTAL
Intervention: Aggressive antihypertensive treatment to achieve a goal diastolic blood pressure of 80 mm Hg or lower
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin 75 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7767417

Group type: EXPERIMENTAL
Intervention: Ibuprofen syrup (5 mg/kg per dose)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Acetaminophen syrup (10 mg/kg per dose)
Number of subjects: 70
Study: 2252040

Group type: EXPERIMENTAL
Intervention: Ofloxacin (400 mg twice a day)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Erythromycin (400 mg four times a day)
Number of subjects: 87
Study: 7018669

Group type: EXPERIMENTAL
Intervention: BCG immunotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-BCG treatment
Number of subjects: 60
Study: 31707634

Group type: EXPERIMENTAL
Intervention: Manual Acupuncture (MA) stimulation at the lower leg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Manual Acupuncture (MA) stimulation at the ear
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Manual Acupuncture (MA) stimulation at the abdomen
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Manual Acupuncture (MA) stimulation at the forearm
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 60
Study: 27149653

Group type: EXPERIMENTAL
Intervention: Hb content-based study group
Number of subjects: 89

Group type: COMPARATOR
Intervention: Unit-based control group
Number of subjects: 89
Study: 25857500

Group type: EXPERIMENTAL
Intervention: Sudarshan Kriya yoga (SKY) intervention
Number of subjects: 61

Group type: COMPARATOR
Intervention: Standard of care (O-SOC)
Number of subjects: 61
Study: 23823808

Group type: EXPERIMENTAL
Intervention: Pre-ERCP somatostatin (0.5 mg/h for 24 hours, starting 1 hour prior to ERCP)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Post-ERCP somatostatin (0.5 mg/h for 24 hours, starting 1 hour after ERCP)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo (saline for 24 hours, starting 1 hour prior to ERCP)
Number of subjects: 124
Study: 21805410

Group type: EXPERIMENTAL
Intervention: Synbiotic mixture
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 19791493

Group type: EXPERIMENTAL
Intervention: Ultrasonic system (P‐max Newtron)
Number of subjects: 399

Group type: COMPARATOR
Intervention: Conventional round bur
Number of subjects: 399
Study: 16309498

Group type: EXPERIMENTAL
Intervention: Patients with vitiligo
Number of subjects: 57
Study: 14971716

Group type: EXPERIMENTAL
Intervention: Mao-to (herbal medicine)
Number of subjects: 18
Study: 11711931

Group type: EXPERIMENTAL
Intervention: SpaceMaker balloon-assisted advancement flap technique
Number of subjects: 40

Group type: COMPARATOR
Intervention: Advancement flap, turnover flap, transposition flap
Number of subjects: 40
Study: 9024039

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 41

Group type: COMPARATOR
Intervention: Spontaneous ventilation
Number of subjects: 41

Group type: COMPARATOR
Intervention: Controlled ventilation
Number of subjects: 41
Study: 8428715

Group type: EXPERIMENTAL
Intervention: IV cefuroxime (group 1)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Selective parenteral and enteral antimicrobial regimen (group 2)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Selective parenteral and enteral antimicrobial regimen (group 3)
Number of subjects: 104

Group type: COMPARATOR
Intervention: No initial antimicrobials until clinically indicated (group 4)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Selective parenteral and enteral antimicrobial regimen (groups 2 and 3)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Early antimicrobial therapy (groups 1, 2, and 3)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 104
Study: 3314469

Group type: EXPERIMENTAL
Intervention: High-glycemic-index (GI) breakfast foods
Number of subjects: 22

Group type: COMPARATOR
Intervention: Low-glycemic-index (GI) breakfast foods
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Insulin adjustment based on carbohydrate amount
Number of subjects: 22
Study: 29340888

Group type: EXPERIMENTAL
Intervention: Wet Cupping Therapy (WCT) for 10 min
Number of subjects: 57

Group type: COMPARATOR
Intervention: Jiaji acupoint-acupuncture (JA) for 10 min
Number of subjects: 57
Study: 26928677

Group type: EXPERIMENTAL
Intervention: Prophylactic salpingo‐oophorectomy
Number of subjects: 195
Study: 26355881

Group type: EXPERIMENTAL
Intervention: Scaling and root planing plus minocycline microgranules (Test group=T)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Scaling and root planing alone (Control group=C)
Number of subjects: 26
Study: 23331979

Group type: EXPERIMENTAL
Intervention: Fundamentals of Surgery Curriculum (FSC), 96 cases completed before internship orientation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no FSC accounts)
Number of subjects: 20
Study: 21796252

Group type: EXPERIMENTAL
Intervention: Olmesartan plus Azelnidipine (16 mg daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Olmesartan plus Amlodipine (5 mg daily)
Number of subjects: 50
Study: 19924353

Group type: EXPERIMENTAL
Intervention: Nutrition education program coordinated by Nutrition Coordinators
Number of subjects: 352

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 352
Study: 16998093

Group type: EXPERIMENTAL
Intervention: Lower body positive pressure (LBPP) of 40 mm Hg via antishock trousers
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control period
Number of subjects: 11
Study: 15311657

Group type: EXPERIMENTAL
Intervention: Broad range of spatial frequencies in audiovisual speech perception task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-pass filtered images
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spatial frequency band-pass filtered images
Number of subjects: 0

Group type: COMPARATOR
Intervention: Viewing distance (not influenced)
Number of subjects: 0
Study: 10951632

Group type: EXPERIMENTAL
Intervention: Cisapride (0.2 mg/kg/dose every 8 hours for 14 days)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 49
Study: 9028717

Group type: EXPERIMENTAL
Intervention: Fish oil supplement (35 mg of 20:5 omega 3 + 22:6 omega 3.kg body weight‐1.day‐1)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Linseed oil supplement (35 mg of 18:3 omega 3.kg body weight‐1.day‐1)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Olive oil supplement (placebo, 35 mg of 18:1.kg body weight‐1.day‐1)
Number of subjects: 28
Study: 8281591

Group type: EXPERIMENTAL
Intervention: Midazolam (0.2‐0.3 mg.kg‐1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Diazepam (0.3‐0.4 mg.kg‐1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Flunitrazepam (0.03‐0.04 mg.kg‐1)
Number of subjects: 30
Study: 3046411

Group type: EXPERIMENTAL
Intervention: Intravenous glucose-insulin-potassium infusion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional subcutaneous insulin administration
Number of subjects: 20
Study: 29661196

Group type: EXPERIMENTAL
Intervention: Women's Heart Health Programme (intervention)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional sex-neutral cardiac programme (control)
Number of subjects: 100
Study: 28478972

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg once weekly plus topical corticosteroids
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks plus topical corticosteroids
Number of subjects: 740

Group type: COMPARATOR
Intervention: Placebo plus topical corticosteroids
Number of subjects: 740
Study: 26228567

Group type: EXPERIMENTAL
Intervention: Active rTMS (AG)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham rTMS (SG)
Number of subjects: 18
Study: 23954314

Group type: EXPERIMENTAL
Intervention: Infliximab, azathioprine, or both (specific dosages and duration not mentioned)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Mucosal healing at week 26
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Endoscopic response at week 26
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Endoscopic response defined as a decrease from baseline in CDEIS of at least 50%
Number of subjects: 172
Study: 21358435

Group type: EXPERIMENTAL
Intervention: Estimated time limits calculated at 90% MAP during the incremental test
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Estimated time limits calculated at 90% MAP during the randomized workloads test
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Measured ETL during the constant power output test
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Mean difference between measured ETL values during the constant test for incremental test
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Mean difference between measured ETL values during the constant test for randomized constant workloads test
Number of subjects: 25
Study: 18492875

Group type: EXPERIMENTAL
Intervention: Virtual CT sonography guidance for radiofrequency ablation
Number of subjects: 101

Group type: COMPARATOR
Intervention: B-mode sonographic guidance
Number of subjects: 101
Study: 16859226

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 12564611

Group type: EXPERIMENTAL
Intervention: sibenadet (Viozan)
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: sibenadet or placebo (during exacerbation)
Number of subjects: 0
Study: 10389044

Group type: EXPERIMENTAL
Intervention: Physiotherapy treatment
Number of subjects: 81

Group type: COMPARATOR
Intervention: Non-physical activities intervention
Number of subjects: 81
Study: 8912804

Group type: EXPERIMENTAL
Intervention: Smoking in the laboratory
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Smoking at home
Number of subjects: 10

Group type: COMPARATOR
Intervention: Baseline HR values in both environments
Number of subjects: 10

Group type: COMPARATOR
Intervention: Skin conductance (SC) data in both environments
Number of subjects: 10
Study: 1853997

Group type: EXPERIMENTAL
Intervention: Physician counseling and take-home pamphlets
Number of subjects: 339

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 339
Study: 6120142

Group type: EXPERIMENTAL
Intervention: Acebutolol (dosage not specified)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31621423

Group type: EXPERIMENTAL
Intervention: Adolescent only intervention group (A group)
Number of subjects: 791

Group type: EXPERIMENTAL
Intervention: Adolescent and mother intervention group (A+M group)
Number of subjects: 791

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 791
Study: 31217004

Group type: EXPERIMENTAL
Intervention: Outreach practice facilitation intervention
Number of subjects: 36
Study: 28095850

Group type: EXPERIMENTAL
Intervention: Training based on the mhGAP-IG (version 1.0) for GPs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 26378561

Group type: EXPERIMENTAL
Intervention: Low-dose simvastatin and health education
Number of subjects: 655

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 655
Study: 23283370

Group type: EXPERIMENTAL
Intervention: Charnley (composite‐beam) prosthesis
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Exeter (double‐tapered) prosthesis
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: C‐Stem (triple‐tapered) prosthesis
Number of subjects: 120

Group type: COMPARATOR
Intervention: All prosthesis designs
Number of subjects: 120
Study: 21341948

Group type: EXPERIMENTAL
Intervention: Semi-structured interviews
Number of subjects: 8
Study: 19685108

Group type: EXPERIMENTAL
Intervention: Intravenous adenosine 5'-triphosphate (ATP) infusion at a rate of 160 microg.kg(‐1).min(‐1) throughout surgery
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intravenous adenosine 5'-triphosphate (ATP) infusion
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 30
Study: 17334459

Group type: EXPERIMENTAL
Intervention: Desflurane-remifentanil (Group DES-REM)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Total intravenous anesthesia (TIVA) (Group TIVA)
Number of subjects: 40
Study: 15533144

Group type: EXPERIMENTAL
Intervention: Sofradex eardrops instilled perioperatively
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control (no drops)
Number of subjects: 61
Study: 11475457

Group type: EXPERIMENTAL
Intervention: Arch index (Al)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Vertical height of the navicular (NH)
Number of subjects: 272
Study: 9626919

Group type: EXPERIMENTAL
Intervention: 0.5% timolol ophthalmic solution
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 0.5% timolol ophthalmic solution with oral nicardipine (40 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 0.5% timolol ophthalmic solution with oral diltiazem (60 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Oral nicardipine (40 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Oral diltiazem (60 mg)
Number of subjects: 8
Study: 7532742

Group type: EXPERIMENTAL
Intervention: Cisplatin, etoposide, and ifosfamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cisplatin, etoposide, and bleomycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carboplatinum
Number of subjects: 0
Study: 2894747

Group type: EXPERIMENTAL
Intervention: ICI 141.292 (100 mg once daily)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: ICI 141.292 (200 mg once daily)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: ICI 141.292 (300 mg once daily)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11